#MDAConference: Mark Awadalla, Chief Development Officer at Capricor Therapeutics, speaks with Rare Disease Advisor at the @mda.org's 2026 Clinical & Scientific Conference in Orlando, FL, about #Deramiocel—an investigational, allogenic cell therapy to treat #DMD

Watch the interview here 🎥

#MDAConference: Mark Awadalla, Chief Development Officer at Capricor Therapeutics, speaking at the @mda.org's 2026 Clinical & Scientific Conference in Orlando, FL, about deramiocel—an investigational, allogenic cell therapy to treat DMD.

#RareDisease #MuscularDystrophy #Deramiocel #Duchenne

Kuehn Law Investigates Potential Misconduct by Capricor Therapeutics Executives Kuehn Law is probing Capricor Therapeutics for possible breaches of fiduciary duties by its executives involving misleading statements about drug efficacy.

Kuehn Law Investigates Potential Misconduct by Capricor Therapeutics Executives #USA #New_York #Kuehn_Law #deramiocel #Capricor_Therapeutics

Capricor Therapeutics Faces Securities Lawsuit Amid Lead Drug Development Concerns Capricor Therapeutics is facing a lawsuit for securities law violations. Shareholders are urged to contact The Gross Law Firm for assistance.

Capricor Therapeutics Faces Securities Lawsuit Amid Lead Drug Development Concerns #United_States #New_York #Securities_Law #deramiocel #Capricor_Therapeutics

Gross Law Firm Initiates Securities Class Action for Capricor Therapeutics Shareholders The Gross Law Firm has launched a securities class action for shareholders of Capricor Therapeutics Inc. (NASDAQ: CAPR) after misleading information regarding drug approval.

Gross Law Firm Initiates Securities Class Action for Capricor Therapeutics Shareholders #USA #New_York #Securities_Class_Action #deramiocel #Capricor_Therapeutics

Investors Launch Class Action Against Capricor Therapeutics Over Stock Discrepancies A class action lawsuit has been filed against Capricor Therapeutics, Inc. involving misleading statements about its drug under FDA review, impacting investors significantly.

Investors Launch Class Action Against Capricor Therapeutics Over Stock Discrepancies #USA #New_York #Class_Action #deramiocel #Capricor_Therapeutics

Capricor Therapeutics Investors Encouraged to Join Class Action Following Significant Losses Shareholders of Capricor Therapeutics, Inc. are invited to join a class action suit after the company's failure to secure FDA approval for a critical drug caused stock values to plummet.

Capricor Therapeutics Investors Encouraged to Join Class Action Following Significant Losses #United_States #New_York #Class_Action #deramiocel #Capricor

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy Capricor Therapeutics , a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company’s Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. Is Deramiocel FDA Approved? During the meeting, FDA stated that no significant deficiencies have been identified by the Review Committee and that the package is on track for a Prescription Drug User Fee Act (PDUFA) action date of August 31, 2025. The FDA has also confirmed its intent to hold an advisory committee meeting, although an official date has not yet been set.

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

👉 DMDWarrioR.com

#dmd #duchenne #deramiocel #cardiomiopathy

Long-term preservation of muscle function and structure by repeated administration of cardiosphere-derived cells in mdx mice Duchenne muscular dystrophy (DMD) is a progressive disease associated with functional decline. Chronic administration of cardiosphere-derived cell therapy prevents disease-related functional decline f...

Pleased to share out latest work on cell therapy for #Duchenne. We show #deramiocel therapy initiated early protects against disease-related decline in muscle function.

@eduardomarban.bsky.social @smidtheart.bsky.social @stemcellreports.bsky.social @mda.org

Deramiocel Eases Upper Limb Function Decline in Patients With DMD Patients treated with deramiocel demonstrated a 52% attenuation of disease progression compared with matched external patients.

#MDAConference: Study participants w/ Duchenne muscular dystrophy treated with the investigative cell therapy #deramiocel showed a decreased annual decline in upper limb function over a 5-year period that included a 12-month gap period with no treatment

Read more: bit.ly/3XXGU1e

@mda.org #RDAatMDA

NS Pharma Receives FDA Acceptance for Duchenne Muscular Dystrophy Treatment: A Hope for Families NS Pharma's acceptance from the FDA for its cell therapy deramiocel marks a significant advancement in treating Duchenne muscular dystrophy, offering hope to affected families.

NS Pharma Receives FDA Acceptance for Duchenne Muscular Dystrophy Treatment: A Hope for Families #USA #NS_Pharma #Paramus #Duchenne_Muscular_Dystrophy #deramiocel

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy Capricor Therapeutics, a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the U.S. Food and Drug Administration (“FDA”) has accepted for review its Biologics License Application (“BLA”) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (“DMD”) cardiomyopathy.

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

👉 Read More: dmdwarrior.com

#dmd #duchenne #deramiocel #capricor

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy -If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy. -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku.

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #musculardystrophy #Capricor #Deramiocel #fda